IPP Bureau
LEX Diagnostics gets FDA nod and CLIA waiver for ultra-fast VELO system
By IPP Bureau - February 18, 2026
The VELO system supports multiplex testing for Influenza A, Influenza B, and COVID-19, producing PCR results in six to ten minutes
Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI
By IPP Bureau - February 18, 2026
Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC
Scinai acquires Recipharm Israel to expand global reach
By IPP Bureau - February 18, 2026
This transaction fundamentally strengthens Scinai's CDMO platform
FDA accepts Deciphera’s NDA for tirabrutinib in rare aggressive brain lymphoma
By IPP Bureau - February 18, 2026
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program
By IPP Bureau - February 18, 2026
A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula
QCIL to build 350+ bed state-of-the-art CARE Hospital in Nagpur
By IPP Bureau - February 18, 2026
USFDA issues Form 483 with 6 observations to Enzene Biosciences’ Chakan plant following PAI
By IPP Bureau - February 17, 2026
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
Lupin partners with Spektus Pharma to commercialize DeslaFlex antidepressant in Canada
By IPP Bureau - February 17, 2026
DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform
Sanofi Healthcare expands Hyderabad Global Hub, boosts capacity to 4,500 staff
By IPP Bureau - February 17, 2026
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
Lilly’s Retevmo shows major survival boost in early-stage RET fusion lung cancer
By IPP Bureau - February 17, 2026
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Roche’s Gazyva hits major milestone in rare kidney disease
By IPP Bureau - February 17, 2026
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
Ind-Swift Labs to pump Rs. 40 crore into Samba facility for global expansion
By IPP Bureau - February 17, 2026
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Novartis’ Vanrafia shows promise in slowing kidney decline in IgA nephropathy
By IPP Bureau - February 17, 2026
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
Mankind Pharma overhauls global supply chain with AI
By IPP Bureau - February 17, 2026
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
